The Efficacy Of Entecavir For The Treatment Of HBeAg-positive And HBeAg-negative, Chronic Hepatitis B And Liver Cirrhosis

ObjectiveTo evaluate antiviral effects ofEntecavir(ETV) on different types of patients with hepatitis B virus infection(HBeAg-negative and HBeAg-positive, chronic hepatitis B and liver cirrhosis). MethodsAccording to HBeAg condition and progress of disease, one hundred and five cases of CHB were respectively divided into the HBeAg-negative group and the HBeAg-positive group, the chronic hepatitis B group and the liver cirrhosis group. The patients were treated with daily dose of ETV 0.5mg(per os).Observational indexes: Hepatitis B virus DNA levels, liver function and AFP, were measured at baseline, week-4, week-12, week-24 and week-48. ResultsBaseline between the HBeAg-negative group and the HBeAg-positive group, the chronic hepatitis B group and the liver cirrhosis group wasnot statistically significant before ETV treatment(p>0.05).At week-4 with ETV, the ratios of cases with undetectable serum HBV-DNA of the HBeAg-negative group and the HBeAg-positive group were 28% and 8%, which was statistically significant(p<0.05). At week-12, week-24 and week-48 with ETV, the ratios of cases with undetectable serum HBV DNA of the HBeAg-negative group and the HBeAg-positive group were 68%, 85%, 91%and56%, 76%, 84%, which was not statistically significant(p>0.05).At week-4 with ETV,serum HBV DNA levels of the HBeAg-negative group decreased by 1.91±1.00lgIU/ml which was superior to the HBeAg-positive group 1.07±0.78lgIU/m, which was statistically significant(p<0.05). At week-12, week-24 and week-48 with ETV,serum HBV-DNA levelsof the HBeAg-negative group and the HBeAg-positive group decreased by2.27±1.2, 2.51±1.14, 2.53±1.13lgIU/ml and 2.61±1.11, 2.70±1.13, 2.73±1.11lgIU/ml, which was not statistically significant(p>0.05). At week-4,week-12,week-24, week-48 with ETV, the difference of the ALT normalization and the T-BIL normalization was not significant between the HBeAg-negative group and the HBeAg-positive group(p>0.05). At week-4, week-12, week-24 and week-48 with ETV, the difference was not significant between the chronic hepatitis B group and the liver cirrhosis group in ratios of cases with undetectable serum HBV-DNA,the serum HBV-DNA levels decreased, the ALT normalization, the TBIL normalization,the HBe Ag normalization and the HBeAg seroconversion rate(p>0.05).At week-0 and week-48 with ETV, the AFP value of the liver cirrhosis group were different, which was statistically significant(p<0.05). Conclusions(1)Among of four groups, the ETV have good clinical effect in terms of the ratios of cases with undetectable serum HBV-DNA, the HBeAg normalization, HBeAg seroconversion rate, the ALT normalization and the TBIL normalization.(2) The effect of the HBeAg-negative group with domestic ETV therapy was superior to that of the HBeAg-positive group in the early.